Physician profile
Mauricio Silva
NPI 1609162197
$3,460.72
in general payments reported to CMS, 2019-2025
29 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $865 · 2021: $805 · 2022: $403 · 2023: $102 · 2024: $196 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.30 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $462.72 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $444.90 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $362.34 | 2019-2024 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $204.94 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $197.20 | 2019-2022 | |
| Glaxosmithkline, LLC. | $175.75 | 2019-2022 | |
| Amgen INC. | $117.35 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $111.53 | 2019-2021 | |
| Abbvie INC. | $105.78 | 2020-2024 | Vraylar |
| Pfizer INC. | $104.63 | 2019-2021 | |
| Amarin Pharma, INC. | $79.95 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.04 | 2021-2022 | |
| Eisai INC. | $70.31 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $61.00 | 2021-2025 | Fanapt |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.98 | 2021-2022 | |
| Allergan, INC. | $49.33 | 2019-2020 | |
| Indivior INC. | $42.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.47 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $32.82 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $30.46 | 2025 | |
| Avanir Pharmaceuticals, INC. | $29.45 | 2022 | |
| Intra-Sana Laboratories | $19.98 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.83 | 2022 | |
| Dexcom, INC. | $19.52 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $15.76 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.24 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.59 | 2019 | |
| Qiagen, LLC | $12.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauricio Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.